[Medullary thyroid carcinoma: clinical and oncological features and treatment]

Arq Bras Endocrinol Metabol. 2004 Feb;48(1):137-46. doi: 10.1590/s0004-27302004000100015. Epub 2004 Jun 1.
[Article in Portuguese]

Abstract

Medullary carcinoma of the thyroid (MTC) may be sporadic or may occur on a hereditary basis. Hereditary MTC can occur either alone -- familial MTC (FMTC) -- or as the thyroid manifestation of multiple endocrine neoplasia type 2 (MEN 2) syndromes (MEN 2A and MEN 2B) or other forms. Germ-line mutations in RET cause MEN 2. Genetic testing, now available, forms the basis for MTC screening procedures. In the past few years, several genotype-phenotype correlations have focused on the relationship between specific mutations and different MEN 2 syndrome variants. Differences in dimerization induction intensities are a reasonable explanation for the phenotypes resulting from mutations of the different cysteines. Here we described the molecular mechanisms, diagnose and treatment as well as our experience on the management of this rare form of thyroid cancer.

Publication types

  • English Abstract
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Carcinoma, Medullary / diagnosis
  • Carcinoma, Medullary / genetics*
  • Carcinoma, Medullary / therapy*
  • Humans
  • Thyroid Neoplasms / diagnosis*
  • Thyroid Neoplasms / genetics*